+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy of an inactivated vaccine against clinical disease caused by canine coronavirus



Efficacy of an inactivated vaccine against clinical disease caused by canine coronavirus



Advances in Experimental Medicine and Biology 380: 229-234



Canine Coronavirus (CCV) is a causative agent of diarrhea in dogs. The reproduction of severe clinical disease with experimental CCV infection has been difficult. We have recently developed a CCV challenge model which reproduced clinical signs of disease in susceptible dogs. The following study was designed to determine whether immunization with an inactivated CCV vaccine would protect dogs from clinical disease induced using this model. Dogs (n = 13) were vaccinated with an inactivated CCV vaccine. Vaccinates and controls (n = 5) were orally inoculated with virulent CCV virus and treated with dexamethasone on days 0, 2, 4, and 6 after virus challenge. Control dogs developed clinical signs including diarrhea, dehydration, anorexia, depression, and nasal and ocular discharge. Diarrhea was noted in 80% of the controls and 60% progressed to a severe watery or bloody diarrhea that persisted for multiple days. Conversely, only 2/13 (15%) vaccinates developed mild diarrhea and none developed bloody diarrhea. The control dogs averaged 10.8 days of diarrhea compared to 1.4 days for vaccinates over the 21 day observation period. In addition to reduced clinical signs, the number of days of virus shedding and the level of CCV in feces was different for controls (100% shed virus) and vaccinates (38% shed virus). This study demonstrates that vaccination with an inactivated CCV vaccine can significantly reduce not only viral replication, but the occurrence of clinical disease following a virulent CCV infection.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 015677093

Download citation: RISBibTeXText

PMID: 8830484


Related references

Efficacy of an inactivated canine coronavirus vaccine in pups. New Microbiologica 26(2): 151-155, 2003

Inactivated canine coronavirus vaccine us patent 4567042. jan. 28 1986. Official Gazette of the United States Patent & Trademark Office Patents 1062(4): 1588, 1986

Efficacy of a new canine origin, modified live virus vaccine against canine coronavirus. Canine Practice 24(1): 6-9, 1999

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 23(24): 3202-3209, 2005

Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine. Vaccine 30(12): 2228-2235, 2012

Efficacy of an inactivated canine adenovirus-type 2 vaccine. VM SAC veterinary medicine and small animal clinician 78(1): 51-59, 1983

An inactivated Newcastle disease vaccine. Part II: The efficacy of an inactivated, experimental vaccine on the prevention of Newcastle disease. Thai Journal of Veterinary Medicine 33(1): 51-58, 2003

Safety and efficacy of a modified-live canine coronavirus vaccine in dogs. Veterinary Microbiology 99(1): 43-49, 2004

Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus. Vaccine 29(11): 2018-2023, 2011

Efficacy of an inactivated feline panleucopenia virus vaccine against a canine parvovirus isolated from a domestic cat. Veterinary Record 157(10): 285-287, 2005

Efficacy of a combined live attenuated canine distemper and inactivated rabies vaccine in dogs. Indian Journal of Animal Sciences 65(5): 489-491, 1995

Vaccine efficacy and lack of enhanced disease associated with formalin inactivated fi rsv vaccine in cotton rats. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 31: 284, 1991

A novel canine favored CpG oligodeoxynucleotide capable of enhancing the efficacy of an inactivated aluminum-adjuvanted rabies vaccine of dog use. Vaccine 28(12): 2458-2464, 2010

Efficacy of live La Sota Newcastle disease vaccine simultaneously vaccinated with various types of inactivated vaccine. Thai Journal of Veterinary Medicine 23(1): 35-47, 1993

Canine coronavirus vaccine from feline enteric coronavirus. Official Gazette of the United States Patent & Trademark Office Patents 1210(2): 1432, 1998